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Abstract
Advanced glycation end products (AGEs) have long been considered as potent molecules promoting neuronal cell death
and contributing to neurodegenerative disorders such as Alzheimer’s disease (AD). In this study, we demonstrate that AGE-
albumin, the most abundant AGE product in human AD brains, is synthesized in activated microglial cells and secreted into
the extracellular space. The rate of AGE-albumin synthesis in human microglial cells is markedly increased by amyloid-b
exposure and oxidative stress. Exogenous AGE-albumin upregulates the receptor protein for AGE (RAGE) and augments
calcium influx, leading to apoptosis of human primary neurons. In animal experiments, soluble RAGE (sRAGE), pyridoxamine
or ALT-711 prevented Ab-induced neuronal death in rat brains. Collectively, these results provide evidence for a new
mechanism by which microglial cells promote death of neuronal cells through synthesis and secretion of AGE-albumin,
thereby likely contributing to neurodegenerative diseases such as AD.
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Introduction
Alzheimer’s disease (AD) is the one of the most prevalent
neurodegenerative diseases in humans. After the early observa-
tions on the activated microglia and its relation to AD [1–3],
numerous reports indicated that chronic inflammatory processes
contribute to the pathology of AD [4,5]. One of the main central
hypotheses is that the activated microglial cells cause neuronal
damage and contribute to neurodegenerative changes in AD.
After a pilot study of Human Brain Proteome Project, we
recently reported that albumin can be synthesized in microglial
cells in the brain. We also demonstrated that the synthesis and
extracellular secretion of albumin from microglial cells is enhanced
upon microglial activation following Ab1–42 exposure [6]. We
initially proposed that albumin production would be beneficial to
the cells by suppressing Ab polymerization with enhancement of
its clearance [6]. However, the precise role of albumin synthesized
in the brain is still unknown.
Glycation reaction represents a post-translational modification
process between free reducing sugars and free amino groups in
many proteins. Advanced glycation end-products (AGEs), irre-
versible adducts of the Maillard reaction, have been demonstrated
to accumulate in the brain during the course of ageing [7]. In fact,
several reports showed increased AGE levels in the brains of AD
individuals, suggesting pathological roles of AGEs in neurodegen-
erative disorders including AD, where markedly activated
microglial cells and Ab deposition colocalized with AGEs [8–
24]. However, despite these reports, the pathological role and
detailed mechanism of AGEs in promoting neuronal cell death
and neurodegeneration are poorly understood. We hypothesized
that secreted AGEs promote death of neuronal cells through
activating the stress-activated protein kinases, which further
activate cell-death associated Bcl-2 homolog proteins, in the
primary neuronal cells and the brains from AD individuals. The
aims of this study were to determine whether human primary
microglial cells synthesize AGEs as AGE-albumin and to
investigate the mechanism by which secreted AGE-albumin
promotes death of primary neuronal cells, rat brains treated with
Ab1–42 peptide and human brains from AD individuals. Our
results demonstrate that AGE-albumin is not only synthesized in
microglial cells but also promotes death of neuronal cells in
primary culture, Ab1–42-exposed rat brains, and the brains of AD
individuals, ultimately contributing to neurodegeneration.
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1. Ubiquitous Distribution of AGE-albumin in the Brains
of Human AD Individuals and Ab-exposed Rats
To study the mechanisms by which AGE-albumin synthesis is
increased while how it promotes neuronal cell death, we first
investigated the distribution of AGE and albumin in HMO6
microglial cells. Surprisingly, most AGEs were co-localized with
albumin, suggesting that AGE-albumin could be a major AGE
product in microglial cells of the brain (Fig. 1A). To further
demonstrate the co-localization of AGE with albumin, we
performed double immunohistochemical staining in human
HMO6 microglial cells before and after Ab treatment. AGE
levels were markedly increased after Ab exposure and most AGEs
were co-localized with albumin. In addition, the tissue levels of
AGE and albumin were strikingly elevated, and AGE was co-
localized with albumin in Ab–treated rat brains and human brains
of AD individuals compared with control rat and human brains,
respectively (Fig. 1A). Densitometric analysis indicated a 17.9-fold
increase in AGE-albumin in the brains of individuals with AD
(n=5) compared to samples from normal individuals (n=5)
(Fig. 1B). Interestingly, the double-labeled AGE-albumin immu-
noreactive material was highly localized in the vicinity of cells with
apoptotic nuclei. This strongly indicates that AGE-albumin may
be directly involved in cell death in the brain. Immunoblot analysis
of whole cell lysates revealed that the rate of AGE-albumin
synthesis in HMO6 microglial cells was markedly and concentra-
tion-dependently increased following Ab exposure (Figs. 1C, D).
Moreover, immunoblot analysis of rat brain before and after Ab
treatment revealed that the amount of AGE-albumin increased
significantly in cerebrum but not in cerebellum after Ab treatment
into the rat entorhinal cortex (Figs. 1E–H).
2. Synthesis and Secretion of AGE-albumin in Microglial
Cells
Because of the elevated levels of AGE-albumin in 3 different
experimental models, we further investigated the cell-specific
distribution of AGE-albumin in the human primary brain cells.
The microglial marker, Iba-1, was generally co-expressed with
AGE and albumin. In contrast, only limited amounts of the
astrocyte marker (GFAP), the oligodendrocyte marker (Olig2), and
the neuronal marker (NeuroD) were co-localized with AGE-
albumin in human primary brain cells (Fig. 2). Based on these
results, we concluded that AGE-albumin, the most abundant
protein modified by AGE, is produced largely by microglial cells of
the human brain.
Next, we evaluated whether AGE-albumin secretion was
increased when human HMO6 microglial cells were activated
with Ab. Immunoblot analysis of whole cell lysates and ELISA
data for the culture media showed that AGE-albumin synthesis in
human microglial cells and its extracellular secretion were
significantly elevated by 1.6 times after Ab treatment time-
dependently (Figs. 3A, B). When cells were treated with the specific
antibody against albumin, the amount of AGE-albumin was
decreased regardless of Ab treatment.
3. Increased Synthesis and Secretion of AGE-albumin by
Oxidative Stress in Human Microglial Cells
We investigated whether the AGE-albumin synthesis and
secretion are directly reduced by AGE inhibitor (pyridoxamine)
or AGE cross-link breaker (ALT-711). When the HMO6
microglial cells were exposed to pyridoxamine or ALT-711, the
amount of AGE-albumin was dramatically reduced in a concen-
tration-dependent manner (Figs. 3C, D).
Next, we investigated whether the AGE-albumin synthesis and
secretion are directly induced by elevated oxidative stress. When
the HMO6 microglial cells were exposed to a strong oxidant,
hydrogen peroxide, the amount of AGE-albumin was increased in
a concentration-dependent manner (Figs. 3E, F). In contrast,
addition of an anti-oxidant ascorbic acid (Asc) dramatically
decreased the amount of AGE-albumin regardless of Ab treatment
(Figs. 3G, H). These data suggest that the amounts of both
intracellular and secreted AGE-albumin, but not albumin itself,
positively correlated with the degree of oxidative stress. Based on
these findings, we conclude that the Ab–induced synthesis of
AGE-albumin in human HMO6 microglial cells and its extracel-
lular secretion are closely related to increased oxidative stress.
4. Ab Polymerization and Increased Ab Synthesis by AGE-
albumin in Human Microglial Cells
To determine whether AGE-albumin increases Ab synthesis
and accumulation in human microglial cells compared to albumin,
we determined the amounts of Ab, beta-amyloid cleavage enzyme
(BACE), ADAM10 and APP by immunohistochemistry, immuno-
blot analysis, and ELISA respectively. BACE levels were markedly
increased in AGE-albumin-exposed HMO6 cells compared to
untreated or albumin-treated cells whereas the levels of ADAM10
or APP were unchanged (Figure S1).
We next studied the functional role of albumin or AGE-albumin
in Ab aggregation by staining with thioflavin T (ThT), which
reflects the degree of Ab aggregation. The ThT fluorescence assay
revealed that the aggregation of Ab was significantly increased by
1.6 times after addition of AGE-albumin than that with albumin
alone (used as 100% control) (Fig. 3I). ELISA analysis revealed
that the amount of Ab in culture media was dramatically increased
after HMO6 cells were exposed to AGE-albumin compared to
untreated cells or albumin-treated cells (Fig. 3J).
We also hypothesized that increased Ab accumulation may be
promoted by inactivation of a chaperone PDI (protein disulfide
isomerase), which has been shown to be inactivated by S-
nitrosylation in the brains of AD individuals, leading to Ab
accumulation [17]. Immunoblot results of the immunoprecipitated
PDI (55 kDa) revealed that the level of S-nitrosylated PDI was
increased in Ab-exposed HMO6 cells compared to that in
untreated control (Figs. 3K, L). These results suggest that AGE-
albumin increases microglial Ab synthesis and accumulation in a
vicious cycle, which further aggravates the AD conditions through
increased Ab production via up-regulating the BACE level, AGE-
albumin synthesis, and neuronal cell death.
5. Induction of RAGE (Receptor of Advanced Glycation
End Product) and Promotion of Neuronal Apoptosis by
AGE-albumin
A receptor protein for AGEs (RAGE) is known to be expressed
in neurons, while its increased level is highly correlated with
neuronal death and development of AD [16]. In addition, AGE
binds to RAGE in primary neurons [25]. Therefore, we also
assessed whether AGE-albumin can increase production of
RAGE, a strong indicator of neuronal apoptosis in AD [26,27],
leading to cell death in human primary neurons. Immunohisto-
chemical and immunoblot data showed that the amount of RAGE
was significantly increased in primary neurons exposed to AGE-
albumin compared to those untreated or treated with albumin
only (Fig. 4A).
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calcium influx are critically important in initiating apoptosis
[18,19], we monitored the changes in the respective levels of
MAPKs, Bax, mitochondrial calcium influx, and cell death rate in
the human primary neurons. Immunoblot analyses showed that
the levels of pSAPK/JNK, and Bax were significantly increased
after the human neuronal cells were exposed to AGE-albumin
compared to control (albumin alone). But p38K, pp38K, SAPK/
JNK, pSAPK/JNK and Bax levels were decreased dramatically
after the human neuronal cells were exposed to AGE-albumin and
sRAGE (Figs. 4B–D). Microscopic images showed the same
pattern of elevated levels of Bax, which are co-localized with
NeuN and DAPI-stained apoptotic neuronal cells in human AD
brains compared with normal brain tissues (data not shown). In
addition, mitochondrial imaging analysis of living cells showed
that mitochondrial calcium concentration in human neuronal cells
was increased in a time-dependent manner following exposure to
AGE-albumin (Fig. 4E).
Consistent with these results, the optical density for apoptotic
neuronal cells by apoptotic assay increased gradually in a dose-
Figure 1. Distribution and synthesis of AGE-albumin in microglial cells and rat or human brains. (A) Triple-labeled confocal microscopic
image analyses were used to study the distribution and relative levels of albumin (green), AGE (red) and DAPI (blue) in the HMO6 microglial cells and
entorhinal cortex of rat brains before or after Ab treatment as well as cerebral cortex of human brains from normal or AD individuals. HMO6 cells and
rats were treated with Ab1–42 described in the Materials and Methods section. Scale bar=50 mm. These results represent similar images of 5
independent analyses. (B) The AGE-albumin positive particles in cortex of human AD brain were significantly different from the normal brains
(p,0.05), as determined by densitometric analysis using Zeiss Zen 2009 software. (C, D) The degree of AGE-albumin synthesis in HMO6 cells was
determined by immunoblot analysis (C) and densitometric analysis (D) after exposure to different concentrations of Ab1–42, as indicated. The level of
albumin is shown as an internal control for equal protein loading per lane. (E-H) The immunoblots of AGE-albumin in rat cerebrum (E, G) and
cerebellum (F, H), with or without Ab1–42 treatment and densitometric analyses, are shown. *, significantly different (P,0.001) from the level of AGE-
albumin without Ab1–42 treatment.
doi:10.1371/journal.pone.0037917.g001
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(Fig. 4F). In contrast, very few neuronal cells died in the presence
of albumin alone (mg/mL range) (data not shown). Furthermore,
the apoptosis assay showed that apoptosis of neuronal cells
increased after AGE-albumin treatment, but remains same after
co-treatment with AGE-albumin and sRAGE, pyridoxamine or
ALT-711 (Fig. 4G). These data demonstrate that AGE-albumin
directly promotes apoptosis of neuronal cells through activating
the calcium-JNK-Bax pathway, as demonstrated previously in
different cell types [28,29].
6. Protection by Soluble RAGE (sRAGE) Against Ab-
mediated Neuronal Death
To investigate the protective effect of sRAGE against Ab-
mediated neuronal death, we performed in vivo analysis after
injection of Ab alone or co-injection of Ab and sRAGE (Ab/
sRAGE), pyridoxamine (Ab/pyridoxamine) or ALT-711 (Ab/
ALT-711) into rat brain. The relative levels of neurons in rat
brains were dramatically increased at 72 hours after Ab and
sRAGE, pyridoxamine or ALT-711 were co-injected compared to
those administered with Ab alone (Figs. 5A, B). We also studied
whether the activated microglia produces AGE-albumin in rat
brains. Triple labeling confocal microscopy revealed that the
relative numbers of AGE, albumin and Iba1 positive cells were
increased in Ab–injected rat brains, but decreased in Ab/sRAGE
exposed rat brains (Figs. 5C, D).
To investigate whether Ab injection induces neuronal death and
sRAGE protects RAGE-mediated neuronal death, triple labeling
confocal microscopic analysis was performed. The relative
numbers of RAGE positive neurons were increased dramatically
after Ab injection but decreased markedly after Ab/sRAGE co-
injection into rat brains (Figs. 5E, F). Consistently, the numbers of
Bax- and p-JNK-positive neurons were increased markedly after
Ab injection but decreased in Ab/sRAGE co-injected rat brains
(Figs. 5G–I).
Discussion
Many investigators reported importance of activated microglial
cells in various neurodegenerative diseases [1,2,3]. However, it is
poorly understood how activated microglia cells promote neuronal
Figure 2. Synthesis of AGE-albumin in microglial cells but not from astrocytes, oligodendrocytes or neurons from human primary
brain cells. (A) Triple-labeled fluorescent microscopic image analyses were used to demonstrate co-localization of AGE (green), albumin (red), and a
specific marker of different cells (blue) in human primary brain cells. Representative images of microglial cells (Iba1), GFAP (an astrocyte marker), Olig2
(an oligodendrocyte marker), and NeuroD (a neuronal marker) in the human primary brain cells are shown. Similar results were observed in 5
independent analyses. Scale bar=50 mm.
doi:10.1371/journal.pone.0037917.g002
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PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e37917Figure 3. Synthesis of AGE-albumin in human microglial cells and its extracellular secretion. (A) The time-dependent changes in
intracellular (cell lysate) and extracellular (supernatant) AGE-albumin in HMO6 cells, treated with Ab1–42 for 1, 3, 6, 12, 24 h, were determined by
ELISA. (B) The amounts of intracellular (cell lysate) and extracellular (supernatant) AGE-albumin in HMO6 cells, exposed to 3 different conditions as
indicated, were determined by ELISA. The microglial cells were treated with: Ab1–42 alone (5 nM) for 6 h, anti-albumin antibody (ALB Ab, 1 mM) for
24 h, or Ab1–42 treatment after exposure to anti-albumin antibody overnight. (C-H) The amounts of AGE-albumin were determined by immunoblot
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(D), hydrogen peroxide (from 0 to 1,000 mM) (E, F) or 5 mM ascorbic acid (G, H) for 6 h in the absence or presence of 5 nM Ab1–42 peptide. (I)
Relationship between AGE-albumin and Ab, contributing to Ab aggregation. Ab aggregation rates in HMO6 cells, treated with albumin alone or AGE-
albumin, were determined by ThT fluorescence analysis. (H) HMO6 cells were exposed to albumin (ALB) or AGE-albumin (AGE-ALB) for 24 h. The
respective amounts of Ab in the culture media from untreated and AGE-albumin-treated cells were measured by ELISA. (I, J) Increased S-nitrosylation
of PDI in HMO6 cells after treatment with Ab. Microglial cells were exposed to Ab1–42 (400 nM) for 6 h. PDI in whole cell lysates (0.4 mg protein/
sample) was immunoprecipitated with the specific antibody. The immunoprecipitated PDI was subjected to immunoblot analysis with anti-S-NO-Cys
or anti-PDI antibody. *, Significantly different from control or albumin-treated cells by densitometric analysis (p,0.05).
doi:10.1371/journal.pone.0037917.g003
Figure 4. Induction of neuronal cell death by AGE-albumin through up-regulation of RAGE, mitochondrial calcium influx, and
MAPK-Bax pathway. (A) The relative levels of RAGE (green) or DAPI (blue) in human primary neuronal cells, before or after albumin (ALB) or AGE-
albumin (AGE-ALB) treatment for 6 h, were evaluated by double confocal microscopic image analyses. Similar results were observed in 5 independent
analyses. (B) Double confocal microscopic images simultaneously show the neuronal marker (NeuroD) and relative levels of Bax (green), or DAPI
(blue) in human neuronal cells before or after AGE-ALB treatment for 6 h. (C, D) Whole cell lysates (0.01 mg protein/lane) of human neuronal cells,
before or after AGE-albumin exposure, were subjected to immunoblot analysis to determine the levels of ERK1/2, pERK1/2, p38, pp38, pSAPK/JNK,
and Bax with specific molecular weight markers (M). b-Actin was used as an internal control for equal protein loading for each lane. (E) Increased level
of mitochondrial calcium was evaluated by triple labeled confocal microscopic image analysis before (top panel) and after human neuronal cells were
exposed to ALB (middle) or AGE-albumin (bottom): calcium concentration (Fluor-3, green), mitochondria (red), or DAPI-stained nuclei (blue). Scale
bar=50 mm. These results represent similar images of 5 independent analyses. (F, G) The rate of cell death was determined by the apoptosis assay
after human neuronal cells were exposed to different concentrations of AGE-albumin alone. (F), or 20 mg/mL AGE-albumin treatment in the absence
or presence of co-treatment with sRAGE, pyridoxamine or ALT-711 for 24 h (G).
doi:10.1371/journal.pone.0037917.g004
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e37917Figure 5. Protection of Ab-mediated neuronal cell death by sRAGE, pyridoxamine or ALT-711 through decreasing RAGE levels. (A, B)
The relative levels of neurons in rat brains were evaluated by cresyl violet staining after Ab injection without or with sRAGE, pyridoxamine or ALT-711
co-treatment for 72 h. *, Significantly increased in Ab/sRAGE, Ab/pyridoxamine and Ab/ALT-711 co-treated samples compared to Ab treatment only
(p,0.01). (C) Triple confocal microscopic images simultaneously show the relative numbers of AGE, albumin, or Iba1 positive cells in the rat
entorhinal cortex (EC) before or after Ab or Ab/sRAGE injection for 72 h. These results represent similar images of 5 independent analyses. (D) *, The
number of the triple-labeled cells (AGE/albumin/Iba-1 positive cells) significantly increased in whole EC area of Ab injected rat brain but decreased
dramatically in Ab/sRAGE treated rat brain (p,0.01). (E) The levels of RAGE positive neuronal cells were evaluated by triple-labeled confocal
Implication of Microglial AGE-Albumin in AD
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synthesized in microglial cells in the brain [6]. Mass spectral
analysis further confirmed the synthesis of albumin. We also
demonstrated that the synthesis and extracellular secretion of
albumin from microglial cells were elevated upon microglial
activation following Ab1–42 exposure or lipopolysaccharide [6].
Since we did not know the physiological role of albumin in
microglia cells, we initially proposed that albumin production
would be protective against cell death by suppression of Ab
polymerization with enhancement of its clearance [6]. Contrary to
our expectation, we now find a detrimental role of albumin
synthesized in microglial cells. Our current results show that
albumin alone does not affect cell death rate or Ab polymeriza-
tion/aggregation. In contrast, we demonstrate that albumin
synthesized mainly from activated microglial cells is conjugated
with AGE to produce a potently toxic AGE-albumin, which
promotes Ab polymerization and death of neuronal cells in
primary culture. This conclusion was further supported by the
results obtained from animal experiments as well as brain
specimens from AD individuals compared to the corresponding
controls.
To study the mechanism by which AGE-albumin synthesis is
increased and how it promotes neuronal cell death, we first
investigated the distribution of AGE and albumin in HMO6
microglial cells and human AD brains. Surprisingly, most AGEs
were co-localized with albumin (Fig. 1), suggesting that AGE-
albumin could be a major AGE product in microglial cells in the
brain. Interestingly, the double-labeled AGE-albumin signal was
highly localized in the vicinity of the cells with apoptotic nuclei.
Based on our data of the elevated levels of AGE-albumin and co-
localization with apoptotic cells, we concluded that AGE-
albumin, the most abundant protein modified by AGE, is
produced largely by microglial cells but not other cell types in the
rat and human brains. Moreover, immunoblot analysis of whole
cell lysates revealed that the rate of AGE-albumin synthesis in
HMO6 microglial cells was markedly increased in a concentra-
tion-dependent manner following Ab exposure. Taken together,
these results strongly indicate that albumin is synthesized and
secreted mostly as AGE-albumin from microglial cells, and that
both the synthesis and secretion of AGE-albumin are significantly
increased by Ab treatment.
Ab1–42, which increases AGE-albumin synthesis, is known to
exert its toxicity through increased oxidative stress [16]. In our
data, the amounts of both intracellular and secreted AGE-
albumin, but not albumin itself, positively correlated with the
degree of oxidative stress. Based on the data from hydrogen
peroxide and ascorbic acid experiments, we conclude that Ab–
mediated increased oxidative stress is responsible for the synthesis
and its extracellular secretion of AGE-albumin in human HMO6
microglial cells.
Several studies reported that AGEs are localized in the senile
plaques and extra-cellular spaces [8,9,11,13,16,25]. In addition,
albumin was known as a potent inhibitor of Ab polymerization
and the amyloid inhibitory activity isolated from CSF and plasma
was ascribed to the presence of albumin [25], suggesting that
albumin may directly interact with Ab. Our results show that
AGE-albumin is closely associated with Ab in HMO6 microglial
cells, in neurons of Ab-exposed rat brains, and human AD brains.
But it is largely unknown whether the amount and distribution of
AGE-albumin, the most abundant and modified protein synthe-
sized in microglial cells, correlate positively with amyloid plaques.
Our data indicate that AGE-albumin increases microglial Ab
synthesis and accumulation in a vicious cycle, which further
aggravates the AD conditions through increased Ab production
via up-regulating the BACE level, AGE-albumin synthesis, and
neuronal cell death. Furthermore, our data showed that the
increased Ab accumulation is likely promoted through inactivation
of a chaperone PDI, as exemplified in the brains of AD
individuals, leading to Ab accumulation [15].
Increased level of RAGE, known to be expressed in neurons,
highly correlated with neuronal death and development of AD
[16]. In addition, AGE binds to RAGE in primary neurons [25].
Our immunohistochemical and immunoblot data showed that the
amount of RAGE was significantly increased in primary neurons
exposed to AGE-albumin compared to those untreated or treated
with albumin alone. Since the stress-activated protein kinases and
increased mitochondrial calcium influx are critically important in
initiating apoptosis [26,27], we also evaluated the effects of AGE-
albumin on the respective changes of MAPKs, Bax, mitochondrial
calcium influx, and cell death rate in the human primary neurons.
Our data demonstrate that AGE-albumin directly promotes
apoptosis of neuronal cells through activating the calcium-JNK-
Bax pathway, as demonstrated previously in other cell types
[28,29].
The sRAGE is an extracellular component of RAGE and can
inhibit AGE-RAGE interaction by binding AGE in extracellular
spaces [11,16]. Our results revealed that sRAGE protected Ab–
induced neuronal death when it was injected into rat brain
together with Ab. We also showed that the activated microglia
produces AGE-albumin in rat brains after Ab injection. Moreover,
the number of AGE-albumin positive activated microglia was also
decreased in Ab/sRAGE co-injected rat brains. The relative
numbers of neurons positive with RAGE, Bax, and p-JNK were
increased dramatically in Ab injected rat brains but markedly
decreased after Ab/sRAGE co-administration. These in vivo results
were consistent with our in vitro data observed with human
microglial cell line or human primary neuronal cells.
In summary, our current data show for the first time that AGE-
albumin, the most abundant form of brain AGEs, is synthesized in
microglial cells and secreted into extracellular space. The rate of
AGE-albumin synthesis is markedly increased by Ab treatment
and increased oxidative stress while its elevated levels are
frequently observed in the human brains of AD individuals
compared with controls. AGE-albumin also promotes Ab aggre-
gation in microglial cells. Furthermore, AGE-albumin promotes
the calcium-JNK-Bax-mediated apoptosis in primary neurons
from AD individuals (Figure S2). Our results, therefore, provide a
new mechanistic insight by which microglial cells play an
important role in promoting neuronal death in human primary
cells from AD individuals and Ab-exposed rat brains by
synthesizing and secreting potentially toxic AGE-albumin. Finally,
AGE-albumin could be an excellent biomarker as a therapeutic
target for neurodegenerative diseases including Alzheimer’s
disease.
microscopic image analysis in entorhinal cortex of control, Ab,o rA b/sRAGE injected rat brains. (F) *, The number of RAGE positive neuronal cells
significantly increased in Ab injected rat brain but decreased dramatically in Ab/sRAGE treated rat brain (p,0.01). (G-I) The number of Bax or pSAPK/
JNK positive neurons was evaluated by confocal microscopy. (H, I) *, The number of Bax positive neuronal cells (H) or pSAPK/JNK positive neuronal
cells (I) significantly increased in Ab injected rat brain but decreased dramatically in Ab/sRAGE treated rat brain (p,0.01). Scale bar=50 mm.
doi:10.1371/journal.pone.0037917.g005
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Cell Culture
For in vitro studies, an immortalized human microglial cell line
(HMO6) was used. HMO6 cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM, Gibco) containing a high
glucose concentration supplemented with 10% heat-inactivated
fetal bovine serum (FBS, Gibco) and 20 mg/ml gentamycin
(Sigma-Aldrich). These cells were maintained at 37uC under 5%
CO2. HMO6 cells were exposed to Ab1–42 (Sigma-Aldrich) at
concentrations from 0 up to 400 or 5 nM. For inhibition studies,
HMO6 cells were exposed to pyridoxamine (Sigma-Aldrich) for
3 h at concentrations from 0 up to 1 mM or ALT-711 (BioTrader)
for 1 h at concentrations from 0 up to 5 mM before 5 nM Ab1–42
treatment. HMO6 cells were then harvested 6 h after Ab1–42
treatment for further analysis.
Primary Culture of Human Neuronal Cells
Primary human neuronal cells were prepared from human
brain tissues. The brain tissue collection and usage were approved
by the Ethics Committee of the Seoul National University College
of Medicine, Seoul, Korea. Human primary neurons were
prepared as previously described [30]. In brief, small pieces of
human brain cortexes were incubated with phosphate-buffered
saline (PBS) containing 0.25% trypsin and 40 mg/ml DNase I for
30 min at 37uC. Dissociated cells were suspended in 5%
decomplemented serum in high glucose-containing minimal
essential medium with Earle’s salts, 1 mM sodium pyruvate, and
2 mM glutamine. All glial cells were removed and these neuronal
cells were maintained at 37uC under 5% CO2 for further
experiment.
Human Neuronal Cells
Primary human neuronal cells were purchased from Science-
Cell Research Laboratories (HN 1520). Human neuronal cells
were grown in Neuronal Medium (NM 1521) according to the
manufacturer’s suggestion for 2 days before AGE-albumin
treatment.
AGE-albumin and Ab
AGE-albumin (A9810) and monomeric Ab1–42 (A8301) were
purchased from Sigma-Aldrich. Oligomeric Ab was produced
from monomeric Ab by the previously published method [31,32].
Immunocytochemistry (ICC)
Cells were grown on Lab-Tek II slide chambers (Nunc), rinsed
with PBS, fixed in methanol for 15 min, and rinsed again with
PBS. The fixed cells on slide chambers were incubated overnight
at 4uC with the following primary antibodies: rabbit anti-AGE
antibody (1:200, Abcam), mouse anti-human-albumin antibody
(1:200, R&D System), anti-BACE antibody (1:50, Santa Cruz),
anti-ADAM10 antibody (1:200, R&D System), anti-APP antibody
(1:200, Chemicon), anti-RAGE antibody (1:50, Santa Cruz), or
anti-mitochondria antibody (1:50, Abcam). After overnight incu-
bation, the primary antibodies were washed with PBS three times
and the slides were incubated for 1 h at room temperature with
one of the following secondary antibodies: Alexa Fluor 633 anti-
mouse IgG (1:500, Invitrogen), Alexa Fluor 488 anti-rabbit IgG
(1:500, Invitrogen), or Alexa Fluor 555 anti-goat IgG (1:500,
Invitrogen). After washing the secondary antibodies with PBS
three times at 10-min intervals, coverslips were mounted onto glass
slides using the Vectashield mounting medium (Vector Laborato-
ries), and examined under a laser confocal fluorescence micro-
scope (LSM-710, Carl Zeiss).
Animals
Thirty adult male Sprague-Dawley rats (230–350 g) were used
in this study. The rats were maintained on a 12-h light-dark cycle,
had access to food and water ad libitum, and were acclimated for at
least 1 week prior to usage. All animal experiments were approved
by the Institute Animal Care and Use Committee of Lee Gil Ya
Cancer and Diabetes Institute of Gachon University and
conducted humanely.
Entorhinal Cortex Ab or sRAGE (Soluble RAGE) or ALT-711
Injection
Animals were anaesthetized with ketamine HCl (0.75 mg/kg
body weight) and xylazine (1 mg/kg body weight) prior to surgical
procedures. For in vivo treatments, Ab1–42 peptide was dissolved in
theartificial cerebrospinal fluid(ASCF,fromTocrisBioscience)at a
concentration of 400 mM and kept at 4uC until use. Ab1–42 was
injected into the entorhinal cortex (EC) with the aid of a stereotaxic
instrument,followingthemidlineincisionofthescalpskin.Theskull
waspiercedwithabiologicalelectricdrillatthebregma(posteriorly,
8.3 mm; laterally, 5.4 mm) and the needle (30 gauge) on a 5 mL
Hamilton syringe was lowered vertically until it reaches the target
areas(depth,4.5 mm).Threemicrolitersof200 mMAb1–42diluted
in ASCF or 3 mL of ASCF (as a negative vehicle control) were
injected slowly at the rate of 1 mL per minute with an automatic
microinjector. Then the syringe was removed slowly and surgical
woundsweresuturedwithwoundclipsfollowedbytopicaltreatment
with antibiotics. To determine the protection by sRAGE or ALT-
711, five rats were co-injected with Ab1–42 and 3 mL of 6.7 nM
sRAGE or 3 mL of 40 mM ALT-711.
Tissue Preparation
Most rats were allowed to recover for a total of 3 days post
injection. After full recovery, all rats were re-anaesthetized by the
same manner and perfused trans-cardially with 100–200 mL of
heparinized saline at 18uC followed by 400 mL of 4% parafor-
maldehyde-lysine periodate in 0.1 M sodium phosphate buffer
(pH, 7.4). The brains were removed, placed in the same fixative
for 4 h at 4uC, and then transferred into ice-cold 0.1 M
phosphate-buffered saline (PBS) containing 20% sucrose. The
brains were cut in a transverse plane at 10 mm thickness with a
freezing microtome and were stored at 280uC until use.
Immunohistochemistry (IHC)
Human brain tissues from normal adults and AD individuals
were obtained from the Brain Bank of Seoul National University
Hospital and the Brain Bank of Niigata University Hospital. The
collection and use of human brain tissues were approved by the
Institutional Review Board of Clinical Research Institute, Seoul
National University Hospital and Niigata University Hospital,
respectively. Brain tissues were fixed in 4% paraformaldehyde in
0.1 M neutral phosphate buffer, followed by cryoprotection in
30% sucrose solution overnight, and then 10 mm sections were
prepared with a cryostat (Leica CM 1900). Paraffin-embedded
brain tissues were cut into 4 mm-thick sections, deparaffinized with
xylene, and rehydrated with a series of graded ethanol. Normal
goat serum (10%) was used to block non-specific protein binding.
Other staining methods were the same as described in the
immunocytochemistry.
Enzyme-linked Immunosorbent Assay (ELISA)
The amounts of AGE-albumin or Ab in the extracellular culture
media and cell lysates were determined by double ELISA using
rabbit anti-Ab, anti-AGE antibody and mouse anti-human ALB
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measured in duplicate. We coated the 96-wells by incubation with
an anti-ALB antibody (1:800, Abcam). The unbound anti-ALB
antibody was washed with 16PBS three times at 10 min intervals.
Filtered extracts using Amicon filter (cut-off 3 kD) from culture
media or cell lysates were then added into each well and incubated
for 1 h to be captured by the bound anti-ALB antibody. The
unbound proteins were washed off from each well by washing with
16PBS three times at 10 min intervals. After washing the
unbound ALB, the second anti-AGE antibody (1:1000, Abcam)
was added to each well to allow interaction with AGE of the
captured ALB-AGE. The unbound anti-AGE antibody was then
washed off with 16PBS three times before HRP conjugated anti-
rabbit secondary antibody (1:1000, Vector Laboratories) was
incubated for additional 1 h. After washing the unbound HRP-
conjugated secondary antibody, color was developed by incuba-
tion with 3,39, 5,59-tetramethylbenzidine (TMB) for 15 mins, and
reaction stopped with an equal volume of 2 M H2SO4.
Absorbance in each well was measured at 450 nm using an
ELISA plate reader (VERSA Max, Molecular Devices).
Co-immunoprecipitation
Whole cell lysates from HMO6 before and after Ab treatment
were prepared with RIPA buffer containing 1 M Tris (pH 7.5),
5 M NaCl, 10% NP-40, 10% deoxycholate and protease inhibitor
cocktail (Calbiochem). The experiment was repeated three times.
Whole cell lysates (0.5 mg protein) were incubated with 5 mgo f
anti-AGE (Abcam) or anti-protein disulfide isomerase (PDI) for
4 h followed by overnight incubation with protein G-agarose in
500 ml PBS overnight at 4uC. The agarose beads were precipitated
by centrifugation at 14,000 rpm for 5 min, and washed three
times with 1 ml washing buffer containing 50 mM Tris–Cl and
500 mM NaCl (pH 8.0). The immunoprecipitated proteins were
resolved on a 4–12% polyacrylamide gel (Invitrogen), and
subjected to immunoblot analysis with the respective antibody as
follows: anti-AGE antibody (1:1000, Abcam), anti-albumin anti-
body (1:1000, Abcam), anti-PDI antibody (1:200, Santa Cruz), or
anti-S-NO-Cys antibody (1:200, Sigma).
Immunoblot Analysis
Whole cell lysates were prepared with RIPA buffer containing
4% CHAPS. Proteins from each group were separated in 4–12%
polyacrylamide gels (Life Technology) and transferred to nitrocel-
lulose membranes. The primary antibodies used were: anti-BACE
(1:200, Santa Cruz); anti-ADAM10 (1:1,000, R&D System); anti-
APP (1:1,000, Chemicon); anti-RAGE (1:200, Santa Cruz), and
anti ß-actin (1:1,000, Cell Signaling).
ThT Fluorescence Assay
ThT fluorescence assays were performed with synthetic Ab1–42
(Sigma-Aldrich) as described previously with constant shaking for
2.5 h at 37uC. Albumin and AGE-albumin were added at 10 mM
each. ThT emission fluorescence was measured at 483 nm
(450 nm excitation) with a Perkin-Elmer luminescence spectro-
photometer LS-55. Fluorescence values for albumin- or AGE-
albumin-exposed cells were normalized to the DMSO-treated
negative control and expressed as percentage relative fluorescence.
Apoptosis Detection Assay
HT Titer TACS Assay kit (R&D systems) was used to detect
apoptotic neuronal cells after AGE-ALB treatment by following
the manufacturer’s protocol. Briefly, human neuronal cells grown
in 96-well plates were fixed with 4% formaldehyde for 7 min
followed by proteinase K incubation for 15 min. The neuronal
cells in each well were then labeled with TdT (Terminal
deoxynucleotydil transferase) for 60 min and washed to remove
the excess TdT reagent. The cells were incubated with
Streptavidin-HRP for 1 h, followed by removal of the unbound
Streptavidin-HRP, the HRP enzyme reaction was performed by
TACS-Sapphire. By stopping the reaction with 5% phosphoric
acid, apoptotic cells in each plate were determined by fluoro-
cytometry at 450 nm.
Calcium Imaging
Primary human neuronal cells were grown on Lab-Tek II glass
slide chambers (Nunc). After 2 days of cell culture, cells were
incubated with 4 mM Fluo-3 dye (Life Technology) for 40 min at
37uC. After incubation with Fluo-3 dye, the cells were subjected to
image analysis with a laser confocal fluorescence microscope (LSM
710, Carl Zeiss). Upon adjusting proper fields, 100 ng/ml of AGE-
albumin was carefully added into the slide chamber to record any
changes in intracellular calcium levels during the first 20 min.
Densitometry and Statistical Analysis
The densitometric intensity of each immunoreactive band was
determined by using a gel digitizing Image-Pro software. All data
in this report represent the results from at least 3 independent
experiments, unless stated otherwise. Statistical analyses were
performed using the Student’s t test and p,0.05 was considered
statistically significant.
Supporting Information
Figure S1 Increased Ab synthesis through up-regulation of
BACE following AGE-ALB treatment. (A) The relative amounts of
APP, ADAM10, or BACE were studied by immunoconfocal
microscopic image analysis after HMO6 cells were treated with or
without AGE-albumin (AGE-ALB). Scale bar=50 mm. (B, C)
Whole cell lysates (0.01 mg protein/lane) were used to determine
the levels of BACE, ADAM10, and APP in HMO6 cells before or
after AGE-ALB treatment by immunoblot analysis. b-Actin level is
shown for comparable protein loading per lane. (D, E) Whole cell
lysates (0.01 mg protein/lane) of HMO6 cells after AGE-albumin
exposure were prepared and used for immunoblot analysis to
determine the levels of Ab.
(PDF)
Figure S2 A proposed model of AGE-albumin mediated
neuronal cell death and its contribution to AD. The schematic
diagram illustrates the synthesis in microglial cells and extracel-
lular secretion of AGE-albumin, which induces neuronal cell death
and ultimately contributes to neurodegeneration. AGE-albumin
synthesis and secretion in microglial cells is increased upon Ab
treatment. Consequently, elevated amounts of AGE-albumin are
ubiquitously distributed in the brain cortex of AD individual.
AGE-albumin then increases RAGE expression and mitochondri-
al calcium influx, leading to apoptosis in primary neurons. The
microglial cells may also play an important role in neuronal cell
death in AD by synthesizing and secreting AGE-albumin, which
promotes Ab production and aggregation in microglial cells.
Taken together, AGE-albumin promotes death of primary
neuronal cells, and of neurons in rat brains, and human brains,
likely contributing to neurodegenerative diseases including AD.
(PDF)
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